Pharma & Biotech Global Week in Review 23 Nov 2011 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

Australia: APO: Hospital and doctor dispute on the duty to invent ends in 1-1 draw: Royal Children’s Hospital v Robert Alexander (IP Whiteboard) (Patentology)

US: FAIR Generics Act makes its debut; the bill takes a new tack in addressing patent settlement agreements (FDA Law Blog) (Patent Docs)

10 years of TRIPS and public health: an anniversary to celebrate? (IP Watch)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

10 years of TRIPS and public health: an anniversary to celebrate? (IP Watch)

Doha+10: Médecins Sans Frontières asks, what’s next for TRIPS and health? (IP Watch)

Like two ships passing in the night: U.S. and Europe consider patent eligibility of biological materials (Patent Docs)

Comparative study on patenting of human embryonic stem cells (Patent Docs)

WHO CEWG to pave the way for binding global convention on biomedical R&D (KEI)

WTO, WHO, WIPO to discuss TRIPS and health declaration (IP Watch)

Australia: APO: Hospital and doctor dispute on the duty to invent ends in 1-1 draw: Royal Children’s Hospital v Robert Alexander (IP Whiteboard) (Patentology)

Philippines: Wikileaks and Philippines IPR protection – lobbying by Pfizer against Cheaper Medicines Act enacted in 2008 not so scandalous (IP Komodo)

US: FDA approves 35 new drugs in FY 2011 (Patent Docs)

US: Pharma company registered lobbying expenditures for USA (KEI)

US: FAIR Generics Act makes its debut; the bill takes a new tack in addressing patent settlement agreements (FDA Law Blog) (Patent Docs)

US: Senators propose legislation to allow for profits on devices for rare diseases, lifting limitations on experts to serve on advisory panels (FDA Law Blog)

US: Brief submitted to Supreme Court in Mayo v. Prometheus Laboratories (Patent Baristas)

 

Products

Antagon (Ganirelix) – Spain: Court orders grant of SPC for Ganirelix and its salts (The SPC Blog)

Asacol (Mesalamine) – US: Warner Chilcott files patent lawsuit against Zydus Cadila (Patent Circle)

Boniva (Ibandronate) – US: NJ District Court dismisses patent use code counterclaim as not valid under current law; all eyes move to the Supreme Court Prandin use code case: Hoffmann-La Roche v. Orchid Chemicals & Pharmaceuticals (FDA Law Blog)

Codiovan (Valsartan/ Hydrochlorothiazide)  – Germany: Düsseldorf Novartis/Actavis order now in English too (The SPC Blog)

Cotareg (Valsartan/Hydrochlorothiazide) – France: SPC – Novartis v Actavis (Valsartan): the sequel (Kluwer Patent Blog)

Effexor(Venlafaxine) – Australia: FCAFC: Successful appeal paves the way for generic Effexor-XR: Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth Australia Pty Ltd (Patentology)

Nexavar (Sorafenib) – India: Bombay HC sends Bayer’s petition against NATCO’s CL to the Delhi HC (Spicy IP) (Patent Circle)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: